MARKET

SUPN

SUPN

Supernus Pharma
NASDAQ
34.11
+0.37
+1.10%
After Hours: 34.11 0 0.00% 16:00 03/28 EDT
OPEN
33.84
PREV CLOSE
33.74
HIGH
34.39
LOW
33.47
VOLUME
491.01K
TURNOVER
0
52 WEEK HIGH
39.09
52 WEEK LOW
21.99
MARKET CAP
1.87B
P/E (TTM)
1439.24
1D
5D
1M
3M
1Y
5Y
Biotech Stocks Facing FDA Decision In April 2024
NASDAQ · 23h ago
Weekly Report: what happened at SUPN last week (0318-0322)?
Weekly Report · 4d ago
Weekly Report: what happened at SUPN last week (0311-0315)?
Weekly Report · 03/18 11:26
Weekly Report: what happened at SUPN last week (0304-0308)?
Weekly Report · 03/11 11:22
Supernus to Participate in Two Upcoming Investor Conferences
Supernus Pharmaceuticals, Inc. Is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. Jack Khattar, President and CEO of Supernus, will participate in the following investor conferences in March.
Barchart · 03/06 15:30
Supernus Pharmaceuticals: Moving Through An 'Inflection Year'
Seeking Alpha · 03/04 16:41
Weekly Report: what happened at SUPN last week (0226-0301)?
Weekly Report · 03/04 11:26
Supernus Pharmaceuticals Enhances Executive Compensation Packages
TipRanks · 02/28 22:22
More
About SUPN
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Webull offers Supernus Pharmaceuticals Inc stock information, including NASDAQ: SUPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SUPN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SUPN stock methods without spending real money on the virtual paper trading platform.